Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15030812
Abstract: The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins that… read more here.
Keywords: new drugs; drugs face; protacs new; ubiquitin ligase ... See more keywords